CLOs on the Move

Muse bio

www.musebio.com

 
Muse bio is transforming genome engineering by enabling, for the first time, high throughput massively-multiplexed CRISPR editing of proteins, pathways, and genomes. Through our powerful bioinformatics and novel molecular approach, ForgeCraft generates low-cost libraries of thousands of designer protein, pathway, or genome variants each with specifically defined, trackable mutations. This allows the impact of specific changes to be determined through rapid selection and high throughput screening allowing research timelines and costs to be reduced.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.musebio.com
  • 4001 Discovery Dr Suite N321, UCB 027
    Boulder, CO USA 80309

Executives

Name Title Contact Details

Similar Companies

Vaxin

Vaxin is a clinical stage immunotherapeutic biotechnology company located in Montgomery County, MD with additional operating sites in London, UK and Strasbourg, France. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Vaxin is able to rationally design and rapidly develop immunotherapeutic products tailored to address the a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer with fundamental advantages over competing products. Our mission at Vaxin is to protect and preserve public health by providing effective and safe vaccines that prevent disease outbreak.

The Canadian Cancer Research Group

The Canadian Cancer Research Group is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Citra-Solv

Citra-Solv LLC is a Ridgefield, CT-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Annexon Biosciences

Annexon is a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders of the body, brain and eye. The company`s pipeline is based on its platform technology addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway: ANX005 (intravenous administration), ANX007 (intravitreal administration) and ANX009 (subcutaneous administration). Annexon is deploying a disciplined, biomarker-driven strategy designed to improve the probability of technical success of its portfolio.

Imerjent

Imerjent is a Wilsonville, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.